Search Results70 results found
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)
Seqirus is officially recognized by the U.S. government as having successfully established domestic manufacturing capability for innovative cell-based seasonal and pandemic influenza vaccines.
Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines
The new pre-filled syringe line has received FDA approval and will support influenza vaccine production for the 2022/23 Northern Hemisphere season and beyond.
Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine
The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.
Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology
New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform.
This year marks the first full season that Seqirus’ portfolio of innovative influenza vaccines provides a differentiated vaccine option for people of all ages who are eligible in the U.S. to receive a flu shot